In accordance with Section 3 of the Articles of Association of Orion Corporation, 400,000 A-shares have been converted into 400,000 B-shares. The conversion has been entered into the Trade Register on 23 September 2011.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 45,247,646 A-shares and 96,010,182 B-shares.
Orion Corporation
| Olli Huotari SVP, Corporate Functions | Jari Karlson CFO |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.